Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Article states that this treatment is New and Historic.
It sounds like CAR-T targeting mutation, or Multi TAA targeting mutation as opposed to antigen, I don't believe targeting a specific mutation is anything new.

Article says T cells were reprogrammed to target a specific mutation of her cancer cells. Did not mention HOW.

The New England Journal of Medicine says T cells that had been genetically engineered to clonally express two allogeneic HLA-C*08:02–restricted T-cell receptors (TCRs) targeting mutant KRAS G12D expressed by the tumors.

https://www.msn.com/en-us/health/medical/portland-doctors-first-in-world-to-apply-new-cancer-therapy-resulting-in-tumor-reduction/ar-AAXYQmq?ocid=msedgdhp&pc=U531&cvid=ce885dae2a3847e285386f5d937b69be

HERE you can find 7 current clinical trials for KRAS G12D
https://ichgcp.net/clinical-trials-registry/research/list?term=KRAS%20G12D

ALSO see: https://www.mycancergenome.org/content/alteration/kras-g12d/